Hemab Therapeutics Welcomes Anant Murthy, PhD, as Chief Operating Officer to Enhance Global Market Access

Hemab Therapeutics Strengthens Leadership with New COO

Hemab Therapeutics, a clinical-stage bio-pharmaceutical company focusing on innovative prophylactic treatments for rare bleeding and thrombotic disorders, has announced the appointment of Anant Murthy, PhD, as its new Chief Operating Officer (COO). This strategic decision, revealed on September 2, 2025, highlights Hemab's commitment to enhancing its global market access and commercial outreach in an arena fraught with pressing patient needs.

A Vision for Change

Dr. Murthy brings a wealth of experience in specialty medicine market access. With an impressive career, he has held pivotal positions such as EMEA General Manager at argenx and Vice President at Alnylam Pharmaceuticals. Murthy has demonstrated an ability to navigate the challenging landscapes of biopharmaceutical commercialization, making him a valuable asset for Hemab's ambitious goals. The company is focused on addressing significant unmet medical needs through its therapies targeting conditions like Glanzmann thrombasthenia (GT) and Von Willebrand disease (VWD).

"We are excited to welcome Anant as our COO. His extensive experience in delivering specialized medicines will play a critical role in ensuring that Hemab’s pioneering treatments reach those who have faced long waits for innovative therapies," said Dr. Benny Sorensen, CEO of Hemab Therapeutics.

Focus on Patient-Centric Solutions

The inclusion of Dr. Murthy aims to spearhead Hemab's global strategy in launching its varied clinical programs, which include treatments for severe bleeding disorders that have remained unaddressed for many years. His proven leadership history showcases his ability to execute successful product launches in high-stakes environments, and he will direct the operations as the company continues to advance its key drug candidates, especially sutacimig for GT and HMB-002 for VWD.

Dr. Murthy expressed his enthusiasm stating, "Joining Hemab is a fantastic opportunity, as the company is deeply committed to serving patients with bleeding disorders that have historically been underserved. I am looking forward to leveraging my experience to build the necessary global infrastructure to bring our groundbreaking therapies to those who need them most."

A Commitment to Innovation

Hemab Therapeutics operates with a strategic framework known as Hemab 1-2-5™, which focuses on creating a robust pipeline of therapeutic options for patients facing serious medical challenges. By fostering collaboration across multiple geographic regions, Hemab aims to revolutionize the treatment landscape for individuals suffering from conditions like Factor VII Deficiency, Von Willebrand Disease, and others.

As Dr. Murthy steps into his role at Hemab, the company is poised to accelerate its innovative approaches with an emphasis on bringing necessary treatment options to patients globally. The future indeed looks promising as Hemab Therapeutics moves forward under strong leadership dedicated to addressing the urgent needs of those affected by complex bleeding disorders.

About Hemab Therapeutics

Headquartered in Cambridge, Massachusetts, and Copenhagen, Denmark, Hemab Therapeutics is dedicated to developing groundbreaking treatments for rare and complex blood disorders. With a comprehensive approach leveraging cutting-edge technologies, Hemab aspires to transform patients' lives and significantly impact their health outcomes. For more information, visit hemab.com, and stay connected through their official social media channels.

Looking Ahead

Under the leadership of Anant Murthy, Hemab Therapeutics is set to strengthen not only its market presence but also its commitment to the patient communities it serves. As the company continues to advance its clinical programs, the potential for life-changing therapies becomes a tangible reality for many who have long awaited viable treatment options.